Flunisolide

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Flunisolide
Flunisolide.png
Flunisolide ball-and-stick.png
Systematic (IUPAC) name
(1S,2S,4R,8S,9S,11S,12S,13R,19S)-19-fluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one
Clinical data
Trade names Aerobid
AHFS/Drugs.com monograph
MedlinePlus a681048
Legal status ?
Routes Inhaled
Pharmacokinetic data
Protein binding 40% after oral inhalation
Half-life 1.8 hours
Identifiers
CAS number 3385-03-3 YesY
ATC code R01AD04 R03BA03
PubChem CID 82153
DrugBank DB00180
ChemSpider 74144 YesY
UNII 78M02AA8KF YesY
KEGG D00324 N
ChEBI CHEBI:5106 YesY
ChEMBL CHEMBL1512 YesY
Synonyms 6α-Fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione acetone cyclic 16,17-acetal
Chemical data
Formula C24H31FO6 
Mol. mass 434.498 g/mol
 N (what is this?)  (verify)

Flunisolide (marketed as AeroBid, Nasalide, Nasarel) is a corticosteroid often prescribed as treatment for allergic rhinitis.[1] In the United Kingdom it was formerly marketed as Syntaris, but this was recently discontinued by the manufacturers.[2]

The principal mechanism of action of flunisolide is to activate glucocorticoid receptors, meaning it has an anti-inflammatory action.

See also[edit]

References[edit]